Acacia Research shrugs off ‘silly’ criticism after swiftly flipping Woodford assets
US buyer describes the low purchase price of Midatech as ‘a function of the tax and accounting treatment’
US buyer describes the low purchase price of Midatech as ‘a function of the tax and accounting treatment’
|
|
ACD transferred eight stakes valued at £150m to Acacia Research last week
|
|
But Woodford Equity Income ACD provides scant detail on when and how much money will be returned to shareholders
|
|
Authorised corporate director’s role in listing unquoted companies in Guernsey brought into the spotlight
|
|
ACD had already halved the weighting in the LF Equity Income fund last week at a 74% loss
|
|
Link Equity Income fund hasn’t signalled how the market sell-off will hit timelines for fund wind down
|
|
Eve Sleep shares are down 99% from IPO price of 101p
|
|
Deteriorating markets and prior funding commitments like Rutherford Health create uphill battle for administrators
|
|
Investors remain in the dark about timelines for the illiquid portfolio
|
|
Current Income Focus pricing effectively targets a yield of 7.5%
|
|
Tony Stenning added to ACD’s fund board
|
|
Schroders, Blackrock and Jupiter have been floated as possible replacements
|
|